Curanex Pharmaceuticals Inc — Form 8-K
Filed August 17, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Curanex Pharmaceuticals filed an 8-K on 2026-08-17 disclosing material modifications to security holder rights and amendments to articles of incorporation/bylaws, effective 2026-08-14. Specific dollar amounts, counterparties, share counts, percentages, and the nature of the modifications are not detailed in the filing header or accessible text provided.
Why this rating
Charter amendments are routine corporate governance filings; without concrete details of the modifications' scope (dilution, voting rights, liquidation preference changes), cannot assess material impact on $5.1M asset company.
Extracted items
- 3.03
- 5.03 charter/bylaw change
- 9.01 exhibits
See more from August 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.